Marksans Pharma Limited (BOM:524404)
India · Delayed Price · Currency is INR 168.15
+0.15 (0.09%)
At close: Apr 2, 2026
Marksans Pharma Revenue
Marksans Pharma had revenue of 7.54B INR in the quarter ending December 31, 2025, with 10.64% growth. This brings the company's revenue in the last twelve months to 28.03B, up 13.29% year-over-year. In the fiscal year ending March 31, 2025, Marksans Pharma had annual revenue of 26.23B with 20.46% growth.
Revenue (ttm)
28.03B
Revenue Growth
+13.29%
P/S Ratio
2.72
Revenue / Employee
15.24M
Employees
1,840
Market Cap
76.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 26.23B | 4.45B | 20.46% |
| Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
| Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
| Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
| Mar 31, 2021 | 13.76B | 2.42B | 21.32% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 79.18B |
| Granules India | 50.92B |
| AstraZeneca Pharma India | 21.77B |
| Caplin Point Laboratories | 20.92B |
| FDC Limited | 20.78B |
| Sanofi India | 19.33B |
| Viyash Scientific | 18.17B |
| Rubicon Research | 15.98B |
Marksans Pharma News
- 3 days ago - Marksans Pharma receives USFDA approval for Benzonatate Capsules - Business Upturn
- 3 days ago - Pharma sector stocks rally sharply today, April 1: Marksans Pharma jumps 6%, Alembic gains 5.37%, Glenmark Pharma surge 4.30% - Business Upturn
- 7 weeks ago - Marksans Pharma Ltd (BOM:524404) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ... - GuruFocus
- 7 weeks ago - Q3 2026 Marksans Pharma Ltd Earnings Call Transcript - GuruFocus
- 7 weeks ago - Pharma sector stocks today, Feb 9: Marksans Pharma up 5%, Shilpa Medicare jumps 6%, Glenmark rises 1.83% - Business Upturn
- 2 months ago - Pharma sector stocks today, Feb 6: Concord Biotech jumps 4.61%, Alembic Pharma falls 4%, Marksans Pharma down 3.48% - Business Upturn
- 4 months ago - Marksans Pharma gets final USFDA approval for Loperamide Hydrochloride Tablets - Business Upturn
- 4 months ago - Marksans Pharma Ltd (BOM:524404) Q2 2026 Earnings Call Highlights: Strong US Growth and ... - GuruFocus